| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$883.1M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $1.08B | Trading Days | 1359 |
| 52W High | 53.00 |
| 52W Low | 6.50 |
| % Off High | −62.26% |
| YTD | 52.91% | 1Y | −58.68% |
| 3Y | −64.66% | 5Y | −92.74% |
| Since incept. (ann.) | −50.64% |
| Ann. Volatility (1Y) | 116.18% | Ann. Volatility (3Y) | 133.82% |
| Sharpe (1Y) | −0.17 | Sharpe (3Y) | 0.42 |
| Max Drawdown (1Y) | −85.92% | Max Drawdown (3Y) | −95.24% |
| Beta (3Y, vs SPY) | 4.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | $1.07B | — |
| MGTX | MeiraGTx Holdings plc | $1.09B | — |
| INBX | Inhibrx Biosciences, Inc. | $1.17B | — |
| NVAX | NOVAVAX INC | $1.21B | 2.9 |
| SANA | Sana Biotechnology, Inc. | $915.6M | — |
| ODTX | Odyssey Therapeutics, Inc. | $914.0M | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.36B | — |
| VIR | Vir Biotechnology, Inc. | $1.49B | — |
| SLDB | Solid Biosciences Inc. | $784.6M | — |
| MAZE | Maze Therapeutics, Inc. | $1.54B | — |
| TSHA | Taysha Gene Therapies, Inc. |
| $1.57B |
| — |
| AURA | Aura Biosciences, Inc. | $728.9M | — |
